Heplisav-B clinical trials
How each study uses Heplisav-B is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Heplisav-B studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 4
Dynavax Technologies Corporation (8) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Baylor Research Institute (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · University of Maryland, Baltimore (1)
Studies
Open first, then newest update. How each study uses Heplisav-B is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- TLR-9 Adjuvanted Vaccination for Chronic Hepatitis BRecruitingPhase 1University of Maryland, BaltimoreNCT04843852Written as Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
- B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-BCompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04193189Written as HEPLISAV-B
- HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing HemodialysisCompletedPhase 1Dynavax Technologies CorporationNCT03934736Written as HEPLISAV-B®
- Safety and Efficacy of a Hepatitis B Vaccine in Immunosuppressed PatientsCompletedPhase 1Baylor Research InstituteNCT04199715Written as Heplisav-B
- HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)CompletedPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT03685708Written as HEPLISAV-B
- Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) PatientsCompletedPhase 3Dynavax Technologies CorporationNCT00985426Written as HEPLISAV-B
- Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus VaccineCompletedPhase 2Dynavax Technologies CorporationNCT00511095Written as HEPLISAV
- A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal DiseaseTerminatedPhase 2Dynavax Technologies CorporationNCT00498212Written as 1018 ISS-HBsAg-Single
- Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on HemodialysisCompletedPhase 3Dynavax Technologies CorporationNCT01195246Written as HEPLISAV
- Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure PatientsCompletedPhase 1Dynavax Technologies CorporationNCT00426712Written as 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen
- A Study of the Immune Response to Heplisav in Healthy Older AdultsCompletedPhase 1Dynavax Technologies CorporationNCT01999699Written as HEPLISAV
- Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® VaccineCompletedPhase 3Dynavax Technologies CorporationNCT02117934Written as HEPLISAV